Oric Pharmaceuticals Inc (ORIC)

Apr 3, 2026, 4:30 PM EDT - 1 day ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2026, 4:32 AM EDT - 4 days ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

Mar 31, 2026, 4:05 PM EDT - 4 days ago

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Mar 27, 2026, 8:30 AM EDT - 9 days ago

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Mar 17, 2026, 5:01 PM EDT - 18 days ago

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Feb 23, 2026, 4:05 PM EST - 5 weeks ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

Feb 18, 2026, 5:14 PM EST - 6 weeks ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 5, 2026, 4:01 PM EST - 2 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Jan 20, 2026, 1:36 PM EST - 2 months ago

ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

Jan 13, 2026, 4:35 PM EST - 2 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:30 AM EST - 2 months ago

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

Jan 6, 2026, 4:05 PM EST - 3 months ago

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 7, 2025, 1:38 AM EST - 4 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript

Dec 5, 2025, 8:00 PM EST - 4 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 1:00 AM EST - 4 months ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST - 4 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST - 4 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 3, 2025, 6:45 AM EST - 4 months ago

Top 3 Health Care Stocks That May Rocket Higher In December

LRMR PRGO

Dec 1, 2025, 8:00 AM EST - 4 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Nov 24, 2025, 4:05 PM EST - 4 months ago

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 4:10 PM EST - 5 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Nov 13, 2025, 4:05 PM EST - 5 months ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 6, 2025, 4:00 PM EST - 5 months ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Oct 27, 2025, 8:30 AM EDT - 5 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Sep 3, 2025, 7:37 PM EDT - 7 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Aug 18, 2025, 4:05 PM EDT - 8 months ago

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

Aug 12, 2025, 4:05 PM EDT - 8 months ago

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

May 29, 2025, 11:15 AM EDT - 11 months ago

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

May 28, 2025, 4:05 PM EDT - 11 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

May 28, 2025, 4:05 PM EDT - 11 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 8:00 AM EDT - 11 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 11 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 22, 2025, 9:15 AM EDT - 1 year ago

ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Mar 25, 2025, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Feb 18, 2025, 4:05 PM EST - 1 year ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Jan 13, 2025, 8:05 AM EST - 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Jan 6, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:30 PM EST - 1 year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 1, 2024, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 9, 2024, 4:15 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 26, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2024, 4:05 PM EDT - 1 year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Aug 5, 2024, 4:15 PM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 17, 2024, 1:00 PM EDT - 1 year ago

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

May 6, 2024, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

Apr 15, 2024, 4:15 PM EDT - 2 years ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 8, 2024, 8:00 AM EDT - 2 years ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting